康华生物
(300841)
| 流通市值：65.20亿 | | | 总市值：71.11亿 |
| 流通股本：1.22亿 | | | 总股本：1.33亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 137,942,758.51 | 1,431,876,597.94 | 1,060,378,720.25 | 741,084,779.28 |
| 营业收入 | 137,942,758.51 | 1,431,876,597.94 | 1,060,378,720.25 | 741,084,779.28 |
| 二、营业总成本 | 112,232,733.05 | 875,179,262.72 | 577,201,604.21 | 365,393,381.89 |
| 营业成本 | 7,686,111.19 | 83,007,303.55 | 60,754,419.45 | 40,452,790.81 |
| 税金及附加 | 533,949.02 | 10,278,938.01 | 6,618,619.59 | 5,259,389.94 |
| 销售费用 | 55,981,177.56 | 547,123,711.92 | 342,928,667.6 | 207,048,027.53 |
| 管理费用 | 23,438,576.84 | 111,272,410.38 | 81,125,872.87 | 54,105,759.96 |
| 研发费用 | 25,052,456.67 | 132,051,132.76 | 92,407,491.66 | 64,526,823.05 |
| 财务费用 | -459,538.23 | -8,554,233.9 | -6,633,466.96 | -5,999,409.4 |
| 其中:利息费用 | 1,115,590.59 | 5,375,722.11 | 3,967,174.6 | 2,669,150.3 |
| 其中:利息收入 | 1,516,930.58 | 12,280,125.92 | 9,079,527.24 | 6,943,109.57 |
| 加:公允价值变动收益 | 106,031.53 | -59,726,140.81 | -8,007,486.61 | -4,577,171.6 |
| 加:投资收益 | 109,780.81 | 891,245.73 | 957,513.83 | 800,421.19 |
| 资产处置收益 | - | -1,794,548.96 | -1,794,548.96 | - |
| 资产减值损失(新) | -80,892.18 | -1,629,924.78 | -1,428,527.86 | 139,172.77 |
| 信用减值损失(新) | -6,364,268.12 | -30,142,222.91 | -11,686,415.3 | -22,072,309.27 |
| 其他收益 | 583,734.28 | 2,988,010.07 | 1,433,364.05 | 1,432,285.31 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 20,064,411.78 | 467,283,753.56 | 462,651,015.19 | 351,413,795.79 |
| 加:营业外收入 | - | 6,270.29 | 15.85 | - |
| 减:营业外支出 | 6,613.79 | 266,636.35 | 214,166.91 | 111,458.98 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 20,057,797.99 | 467,023,387.5 | 462,436,864.13 | 351,302,336.81 |
| 减:所得税费用 | -650,796.71 | 68,371,464.41 | 56,534,637.67 | 44,747,494.91 |
| 六、净利润 | 20,708,594.7 | 398,651,923.09 | 405,902,226.46 | 306,554,841.9 |
| 持续经营净利润 | 20,708,594.7 | 398,651,923.09 | 405,902,226.46 | - |
| 归属于母公司股东的净利润 | 20,708,594.7 | 398,651,923.09 | 405,902,226.46 | 306,554,841.9 |
| (一)基本每股收益 | 0.16 | 3.03 | 3.07 | 2.3 |
| (二)稀释每股收益 | 0.16 | 3.03 | 3.07 | 2.3 |
| 九、综合收益总额 | 20,708,594.7 | 398,651,923.09 | 405,902,226.46 | 306,554,841.9 |
| 归属于母公司股东的综合收益总额 | 20,708,594.7 | 398,651,923.09 | 405,902,226.46 | 306,554,841.9 |
| 公告日期 | 2025-04-19 | 2025-04-19 | 2024-10-29 | 2024-08-17 |
| 审计意见(境内) | | 标准无保留意见 | | |